OnCo
peoplePerson

Neeraj Agarwal

GU oncologist who led TALAPRO-2 and other trials combining PARP inhibitors with hormone therapy.

Medical oncologist and principal investigator of TALAPRO-2 (talazoparib plus enzalutamide) and CONTACT-03. Directs GU oncology at Huntsman and serves as SWOG executive officer.

Role
SWOG Executive Officer, Genitourinary and Early Therapeutics; Professor of Medicine, Huntsman Cancer Institute, University of Utah
Specialisms
Prostate cancerKidney cancerTargeted therapy

Papers

2top
TitleJournalYear
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trialLancet2023
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate CancerFuture Oncology2022

Connected

9top

cancers

2
Prostate cancerRenal cell carcinoma

targets

2
Androgen receptorPARP

drugs

1
ApprovedSmall-molecule PARP inhibitor
Talazoparib · Talzenna

institutions

2
Huntsman Cancer Institute, University of UtahSWOG Cancer Research Network

trials

2
CONTACT-03TALAPRO-2